NEW YORK, Sept. 30, 2013 /PRNewswire-iReach/ -- Clinilabs, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced today that they have begun a Phase I clinical research study of an investigational medication for Type 2 Diabetes Mellitus. The study is being conducted to assess the safety and tolerability of multiple daily doses of the investigational medication over periods of up to 28 days.
Diabetes has become one of the most prevalent diseases in the United States, with approximately 2 million people diagnosed each year. The Center for Disease Control and Prevention estimates that roughly 35% of the population over the age of 20 is pre-diabetic. For those over the age of 65, this number increases to 50%. Clinilabs understands the growing need for treatment options in this field and is dedicated to helping sufferers combat the disease. In response to the study award, Lead Recruiter Carrie Sorkin states: "Patients understand that clinical trials are a great way to find alternative treatment options for diabetes. At Clinilabs, we have seen this first-hand through the great success we have had in our recruitment efforts."
Clinilabs is currently enrolling male and female volunteers, between the ages of 18 and 70, who have been diagnosed with Type 2 Diabetes Mellitus. Any female patients interested in volunteering for this study must not be of childbearing potential. Patients must be on a stable treatment regimen for at least 4 weeks prior to screening and must have a body weight of above 45.0 kg.
Individuals in the Central New Jersey area who would like to participate can contact our dedicated call center at 212-994-4567 to prequalify. Additional information may also be found by visiting www.clinilabs.com/volunteers. If you are a Physician in the New Jersey or New York area and are interested in referring patients for this trial please contact us at email@example.com.
About Clinilabs Inc.
Clinilabs is a full-service contract research organization (CRO) that specializes in early-phase studies, from first-in-human to proof-of-concept, with normal healthy volunteers and patient populations. The company owns and operates two Phase I units in the US, and maintains a network of highly qualified investigator sites for multicenter Phase II studies Worldwide. Specialty projects, including pharmacodynamic, biomarker, cardiac safety, sleep/wakefulness, metabolic, and Japanese bridging are among our strengths. Clinilabs is recognized globally as a leading specialty CRO, offering an alternative to large CROs for specialty projects. For more information, please visit www.clinilabs.com.
Media Contact: Hannah DAoust, Clinilabs, 646-215-6480, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com